Related Experiment Videos
Soluble interleukin 2 receptor in atopic eczema
G B Colver1, J A Symons, G W Duff
1Department of Dermatology, University of Edinburgh.
BMJ (Clinical Research Ed.)
|May 27, 1989
Summary
Serum soluble interleukin 2 receptor concentrations were significantly higher in patients with atopic eczema than in controls. These levels correlated with disease activity, suggesting immune activation in atopic eczema.
Area of Science:
- Immunology
- Dermatology
- Biochemistry
Background:
- Atopic eczema is a complex inflammatory skin condition.
- Understanding the underlying immune mechanisms is crucial for effective management.
Purpose of the Study:
- To investigate the relationship between serum soluble interleukin 2 receptor (sIL-2R) concentrations and disease activity in patients with atopic eczema.
- To assess sIL-2R as a potential biomarker for immune activation in atopic eczema.
Main Methods:
- A longitudinal study involving 15 patients with severe atopic eczema and 19 healthy controls.
- Serum sIL-2R concentrations were measured using enzyme-linked immunosorbent assays (ELISA).
- Clinical disease activity was assessed using standardized scoring methods.
Main Results:
- Patients with atopic eczema exhibited significantly higher median serum sIL-2R concentrations (770 U/ml) compared to controls (300 U/ml).
- Serum sIL-2R levels decreased significantly during treatment.
- A significant positive correlation (R = 0.73) was observed between sIL-2R concentration and clinical disease activity.
Conclusions:
- Cellular immunopathogenic mechanisms play a role in the development of atopic eczema.
- Serum sIL-2R measurements can effectively indicate immune activation in atopic eczema.
- sIL-2R may serve as a valuable tool for monitoring treatment response in atopic eczema patients.